Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 561 Eccles Ave SOUTH SAN FRANCISCO CA 94080-1906 |
Tel: | N/A |
Website: | https://rapt.com |
IR: | See website |
Key People | ||
Brian Wong President, Chief Executive Officer, Director | Rodney K. B. Young Chief Financial Officer | Dirk Brockstedt Chief Scientific Officer |
Michael Listgarten General Counsel | William Ho Chief Medical Officer |
Business Overview |
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors. |
Financial Overview |
For the fiscal year ended 31 December 2023, Rapt Therapeutics Inc revenues decreased from $1.5M to $0K. Net loss increased 39% to $116.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 50% to $93.1M (expense), Stock-based Compensation in SGA increase of 51% to $9.2M (expense). |
Employees: | 131 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $114.66M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$125.81M as of Dec 31, 2023 |
Net annual income (TTM): | -$116.80M as of Dec 31, 2023 |
Free cash flow (TTM): | -$98.17M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 34,799,702 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |